WASHINGTON TRUST Co Increases Stock Position in Eli Lilly and Company $LLY

WASHINGTON TRUST Co grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 18,634 shares of the company’s stock after acquiring an additional 114 shares during the period. WASHINGTON TRUST Co’s holdings in Eli Lilly and Company were worth $14,526,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. PNC Financial Services Group Inc. grew its position in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Scotiabank initiated coverage on shares of Eli Lilly and Company in a research note on Thursday. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. UBS Group boosted their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $999.32.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $12.96 during trading hours on Thursday, hitting $1,030.74. The stock had a trading volume of 741,677 shares, compared to its average volume of 4,056,012. The firm has a market capitalization of $974.45 billion, a price-to-earnings ratio of 67.39, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,031.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a 50 day simple moving average of $815.33 and a two-hundred day simple moving average of $778.16.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.